未登录

Z

Zhiping Yan

fudan university

H指数:28

被引数:3,112

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correlation and consistency analysis between various indirect portal pressure gradients and actual portal pressure gradient

不同间接门静脉压力梯度与实际门静脉压力梯度间的相关性和一致性分析

BMC GASTROENTEROLOGY

IF2.6

2025-04-100

OA

Fine-Needle Portosystemic Pressure Gradient as a Reference for Portal Hypertension in Patients with Intrahepatic Venovenous Shunt: A Prospective Study

细针穿刺门体压力梯度作为肝内动静脉分流患者门静脉高压的参考指标：一项前瞻性研究

JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

IF2.6

2024-12-010

PRE

Sublethal heat treatment enhances lactic acid uptake in macrophages via MCT1, leading to reduced paraspeckle formation and a subsequent decrease in macrophage pyroptosis

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-01-111

OAAI

2 x 3 kW bidirectional output fiber oscillator employing spindle-shaped ytterbium-doped fiber

IF2.8

2024-01-010

PRE

Hepatocellular Carcinoma with Radiological Progression: Lenvatinib Plus PD-1 Inhibitor Combined with Microwave Ablation and Synchronous Transarterial Chemoembolization

放射性进展的肝细胞癌: 来伐替尼联合PD-1抑制剂联合微波消融和同步经动脉化疗栓塞

JOURNAL OF HEPATOCELLULAR CARCINOMA

IF3.4

2023-10-010

OAAI

Efficacy and Safety of Transarterial Chemoembolization with a Three-Stage Mixed Chemoembolic Regimen for Large Unresectable Hepatocellular Carcinoma

经肝动脉化疗栓塞联合三阶段混合化疗栓塞方案治疗不能切除的大肝癌的疗效和安全性

JOURNAL OF HEPATOCELLULAR CARCINOMA

IF3.4

2023-10-012

OAAI

Role of epithelial sodium channel-related inflammation in human diseases

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-07-258

OAAI

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

IF9.1

2023-04-0598

OAAI

Zhou, Jian; Sun, Huichuan; Wang, Zheng; Cong, Wenming; Zeng, Mengsu; Zhou, Weiping; Bie, Ping; Liu, Lianxin; Wen, Tianfu; Kuang, Ming; Han, Guohong; Yan, ZhiPing; Wang, Maoqiang; Liu, Ruibao; Lu, Ligong; Ren, Zhenggang; Zeng, ZhaoChong; Liang, Ping; Liang, Changhong; Chen, Min; Yan, Fuhua; Wang, Wenping; Hou, Jinlin; Ji, Yuan; Yun, Jingping; Bai, Xueli; Cai, Dingfang; Chen, Weixia; Chen, Yongjun; Cheng, Wenwu; Cheng, Shuqun; Dai, Chaoliu; Guo, Wenzhi; Guo, Yabing; Hua, Baojin; Huang, Xiaowu; Jia, Weidong; Li, Qiu; Li, Tao; Li, Xun; Li, Yaming; Li, Yexiong; Liang, Jun; Ling, Changquan; Liu, Tianshu; Liu, Xiufeng; Lu, Shichun; Lv, Guoyue; Mao, Yilei; Meng, Zhiqiang; Peng, Tao; Ren, Weixin; Shi, Hongcheng; Shi, Guoming; Shi, Ming; Song, Tianqiang; Tao, Kaishan; Wang, Jianhua; Wang, Kui; Wang, Lu; Wang, Wentao; Wang, Xiaoying; Wang, Zhiming; Xiang, Bangde; Xing, Baocai; Xu, Jianming; Yang, Jiamei; Yang, Jianyong; Yang, Yefa; Yang, Yunke; Ye, Shenglong; Yin, Zhenyu; Zeng, Yong; Zhang, Bixiang; Zhang, Boheng; Zhang, Leida; Zhang, Shuijun; Zhang, Ti; Zhang, Yanqiao; Zhao, Ming; Zhao, Yongfu; Zheng, Honggang; Zhou, Ledu; Zhu, Jiye; Zhu, Kangshun; Liu, Rong; Shi, Yinghong; Xiao, Yongsheng; Zhang, Lan; Yang, Chun; Wu, Zhifeng; Dai, Zhi; Chen, Minshan; Cai, Jianqiang; Wang, Weilin; Cai, Xiujun; Li, Qiang; Shen, Feng; Qin, Shukui; Teng, Gaojun; Dong, Jiahong; Fan, Jia

Comparing the predictive ability of portoatrial and portocaval gradient after transjugular intrahepatic portosystemic shunt creation for variceal rebleeding

JOURNAL OF GASTROENTEROLOGY

IF5.5

2023-03-092

PRE

Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis

FRONTIERS IN ONCOLOGY

IF3.3

2023-01-198

OAAI

Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-01-104

OAAI

Ibrutinib suppresses the activation of neutrophils and macrophages and exerts therapeutic effect on acute peritonitis induced by zymosan

INTERNATIONAL IMMUNOPHARMACOLOGY

IF4.7

2022-12-015

PRE

Predictive power of portal pressure gradient remeasured shortly after transjugular intrahepatic portosystemic shunt

HEPATOLOGY INTERNATIONAL

IF6.1

2022-11-023

PRE

Comparison of clinical outcomes between cone beam CT-guided thermal ablation and helical tomotherapy in pulmonary metastases from hepatocellular carcinoma (vol 12, 947284, 2022)

FRONTIERS IN ONCOLOGY

IF3.3

2022-10-060

OAAI

Comparison of clinical outcomes between cone beam CT-guided thermal ablation and helical tomotherapy in pulmonary metastases from hepatocellular carcinoma

FRONTIERS IN ONCOLOGY

IF3.3

2022-08-173

OAAI

Regulator of G-protein signaling 14 protects the liver from ischemia-reperfusion injury by suppressing TGF-β-activated kinase 1 activation

IF15.8

2021-12-0627

OAAI

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib

FRONTIERS IN MOLECULAR BIOSCIENCES

IF4

2021-05-2812

OAAI

Random Survival Forests to Predict Disease Control for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib

FRONTIERS IN MOLECULAR BIOSCIENCES

IF4

2021-05-208

OAAI

Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib

FRONTIERS IN ONCOLOGY

IF3.3

2020-12-1819

OAAI

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib

深度学习预测经动脉化疗栓塞联合索拉非尼治疗的不可切除肝细胞癌患者的总生存期

FRONTIERS IN ONCOLOGY

IF3.3

2020-09-3032

OAAI